Why Truvada isn't being used for HIV prevention

Share this article:

On the penultimate day of 2013, the New York Times gave readers a deep dive on Gilead's Truvada for use in preventing HIV, or rather the lack thereof. As the Times notes, the combo drug has seen poor uptake among the gay community for that indication, 18 months after the strategy's FDA approval.

The lack of Truvada prescriptions—particularly among men—was attributed in part to “negative reactions” HCPs have reportedly given men when they brought it up, as well as social stigma: a particularly derogatory label has been used on social networks to describe men who are on the pill and purposefully engaging in risky behavior, NYT reports.

The article also addressed the absence of a public campaign to promote Truvada for prevention, its price, and side effects. Adherence issues, too, were called out.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters